Oncotarget

Reviews:

This article has been corrected. Correction in: Oncotarget. 2018; 9:6658.

Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis

Shufang Fu, Xin Wen, Fei Han, Yin Long and Gaosi Xu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:89364-89374. https://doi.org/10.18632/oncotarget.19382

Metrics: PDF 705 views  |   HTML 1087 views  |   ?  


Abstract

Shufang Fu1,*, Xin Wen2,*, Fei Han3, Yin Long4 and Gaosi Xu1

1 Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, China

2 Grade 2013, School of Stomatology, Nanchang University, Nanchang, China

3 Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

4 Grade 2013, The Second Clinical Medical College of Nanchang University, Nanchang, China

* Co-first authors contributted equally to this work

Correspondence to:

Gaosi Xu, email:

Keywords: aliskiren, hyperkalaemia, kidney injury, cardiovascular disease

Received: November 17, 2016 Accepted: February 22, 2017 Published: July 19, 2017

Abstract

The efficacy and safety of aliskiren combination therapy with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in patients with hypertension and cardiovascular disease remains attractive attention. We searched the Cochrane Central Register, the Clinical Trials Registry, EMBASE, MEDLINE and PubMed for relevant literatures up to January 2017. A total of 13 randomized controlled trials (RCTs) with 12222 patients were included in this study, and the combined results indicated that aliskiren in combination therapy with ACEIs or ARBs had remarkable effects in reducing systolic blood pressure (SBP) [weighted mean differences (WMD), -4.20; 95% confidential intervals (CI) -5.44 to -2.97; I2, 29.7%] and diastolic blood pressure (DBP: WMD, -2.09; 95% CI -2.90 to -1.27; I2, 0%) when compared with ACEIs or ARBs monotherapy, but with significantly increased the risk of hyperkalaemia [relative risk (RR), 1.45; 95% CI 1.28 to 1.64; I2,10.6 %] and kidney injury ( RR, 1.92; 95% CI 1.14 to 3.21; I2, 0%). Besides, there was no significant difference in the incidence of major cardiovascular events (RR, 0.95; 95% CI 0.89 to 1.02; I2, 0%) between the combined therapy and ACEIs or ARBs monotherapy. In conclusion, this meta-analysis demonstrated that aliskiren in combination therapy with ACEs/ARBs could control BP effectively, but is associated with increasing risks of hyperkalaemia and kidney injury, and have no benefit in preventing of major cardiovascular events.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19382